SYNT 101
Alternative Names: SYNT-101Latest Information Update: 09 Jul 2024
At a glance
- Originator Syntis Bio
- Class Obesity therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Clinical Phase Unknown Obesity